All News
Interleukin-37 Targeting in Gout
The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.
Read ArticleRheumNow Podcast- Methotrexate Mechanisms (2.28.20)
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read ArticleMethotrexate and the Risk of Lung Disease
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; r
Read ArticleHyperuricemia Predisposes to Coronary Artery Disease in Men
There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.
Read ArticleRheumNow Podcast- Half-Empty Flu (2.21.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleHypersensitivity Reactions and Gout Tx: Watch the Dose
Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.
Read ArticleRheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleNSAID Safety Guidelines
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complica
Read ArticleDiabetics using SGLT2 Inhibitors have a lower Gout Risk
Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).
Read ArticleA Role for SGLT2 Inhibition in Gout?
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
Read ArticlePredicting Inpatient Gout Flares
Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.
This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.
Read ArticleRheumNow Podcast - The Elusive Hand OA Problem (12.13.19)
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Read ArticleRheumNow Podcast - Monitoring Methotrexate Safety (12-6-19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticlePegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.
Read ArticleACR 2019 - Report From Day 2 (Monday)
Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.
The Safety of Methotrexate
Read ArticlePANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
Read ArticleRheumNow Podcast – Better Ways to Treat Gout (11.8.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleT2T Lowers Mortality in Gout
A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.
Read ArticleNovel Inhibition of MSU Crystal Inflammation
Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.
Read ArticlePatients Prefer Nurse Led Care for their Gout
Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level 6 mg/dl, this goal is seldom achieved ( 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.
Read Article